Daewoong Pharmaceutical "Hoistar Tablets, Phase 2 Clinical Trial for COVID-19 in Mexico"

[Asia Economy Reporter Cho Hyun-ui] Daewoong Pharmaceutical announced on the 14th that it will be the first to enter Phase 2 clinical trials overseas in Mexico for 'Hoista Tablets (active ingredient Camostat Mesylate),' which is being developed as a treatment for the novel coronavirus infection (COVID-19). Hoista Tablets are treatments for chronic pancreatitis and reflux esophagitis after gastrectomy.

This Phase 2 clinical trial will be conducted mainly at the Salvador Zubir?n National Institute of Medical Sciences and Nutrition in Mexico, involving 180 outpatients with mild to moderate COVID-19, divided into two groups, over 40 days. Group A (90 patients) will receive oral Camostat for 14 days, while Group B (90 patients) will be given a placebo of Camostat to compare and evaluate the alleviation of clinical symptoms.

To facilitate overseas investigator-initiated clinical trials, Daewoong Pharmaceutical signed a joint research agreement on August 19 with the Korea Pasteur Institute and the Korea Institute of Radiological & Medical Sciences. Daewoong Pharmaceutical will supply the necessary pharmaceuticals for the clinical trial and support overseas clinical trial approvals. The Korea Pasteur Institute will build and manage the overseas clinical development network, and the Korea Institute of Radiological & Medical Sciences will collaborate on developing the clinical protocol.

Jeon Seung-ho, CEO of Daewoong Pharmaceutical, said, “Starting with this investigator-initiated clinical trial in Mexico, we expect to accelerate the development of Hoista Tablets as a global COVID-19 treatment.” He added, “Daewoong Pharmaceutical will focus its capabilities on accelerating the development of Camostat and other COVID-19 treatments currently under development, such as Niclosamide, to provide various treatment options to all COVID-19 patients.”

This content was produced with the assistance of AI translation services.